2013
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy
Nazif T, Mehran R, Lee E, Fahy M, Parise H, Stone G, Kirtane A. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal 2013, 167: 43-50. PMID: 24332141, DOI: 10.1016/j.ahj.2013.10.013.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa receptor inhibitorsNet adverse clinical eventsMajor adverse cardiac eventsHigh-risk acute coronary syndromesAcute coronary syndromeMajor bleedingCoronary syndromeComposite major adverse cardiac eventsIIb/IIIa receptor inhibitorsGlycoprotein IIb/IIIa inhibitorsEarly invasive management strategyIIb/IIIa inhibitorsInvasive management strategySafety of tirofibanAdverse cardiac eventsSimilar clinical outcomesAdverse clinical eventsUse of tirofibanComparative effectiveness analysisSignificant differencesACUITY trialAcute CatheterizationUpstream tirofibanMultivariable adjustmentUpstream therapy
2011
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011, 7: 74-83. PMID: 21550906, DOI: 10.4244/eijv7i1a14.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsPaclitaxel-eluting stentsMyocardial infarctionIndependent predictorsID-TLRID-TVRCardiac deathCardiovascular eventsSPIRIT IIStent deploymentDrug-eluting stent deploymentPredictors of deathAdverse clinical outcomesCoronary artery diseaseSuperior clinical efficacyIschaemia-driven revascularisationNumber of lesionsArtery diseaseCoronary stentingClinical outcomesClinical efficacyAdverse outcomesPaclitaxel-eluting stent deploymentClinical trials
2009
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga J, Brodie B, Dudek D, Kornowski R, Rabbani L, Parise H, Stone G, Investigators H. Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2009, 54: 1438-1446. PMID: 19796737, DOI: 10.1016/j.jacc.2009.06.021.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, BalloonAnticoagulantsClopidogrelConfidence IntervalsFemaleHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsProportional Hazards ModelsRecombinant ProteinsTiclopidineTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsClopidogrel loading doseHORIZONS-AMI trialElevation myocardial infarctionLoading doseMyocardial infarctionAdverse cardiac event ratesMajor adverse cardiac eventsEvent ratesCardiac event rateLoading dose groupProbable stent thrombosisAdverse cardiac eventsAdverse event ratesPercutaneous coronary interventionHigher bleeding rateBivalirudin monotherapyPrimary angioplastyAnticoagulation regimensCardiac eventsCoronary intervention
2007
Associations of Plasma Natriuretic Peptide, Adrenomedullin, and Homocysteine Levels With Alterations in Arterial Stiffness
Levy D, Hwang S, Kayalar A, Benjamin E, Vasan R, Parise H, Larson M, Wang T, Selhub J, Jacques P, Vita J, Keyes M, Mitchell G. Associations of Plasma Natriuretic Peptide, Adrenomedullin, and Homocysteine Levels With Alterations in Arterial Stiffness. Circulation 2007, 115: 3079-3085. PMID: 17533184, DOI: 10.1161/circulationaha.106.652842.Peer-Reviewed Original ResearchConceptsN-terminal atrial natriuretic peptideCarotid-femoral pulse wave velocityB-type natriuretic peptidePulse wave velocityAtrial natriuretic peptideCarotid-radial pulse wave velocityCentral pulse pressurePlasma natriuretic peptidesNatriuretic peptideArterial stiffnessHomocysteine levelsPulse pressureFramingham Heart StudyHeart StudyPlasma N-terminal atrial natriuretic peptideDiastolic blood pressureMean arterial pressureCarotid pulse pressureArterial wall stiffnessForward pressure waveArterial pressureCentral systolicBlood pressureHomocysteine concentrationsCardiovascular disease